1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow PCI: new trials by email Literature Review of PCI trials Research Report on PCI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment - No Reflow Phenomenon, Reperfusion Injuries, Myocardial | Phase 2 | Not yet recruiting | Al-Azhar University | 100 | 2027-01-01 | 2026-10-27 |
Coronary Artery Disease (1) · Myocardial Infarction (1) · Myocardial Reperfusion Injury (1) · No-Reflow Phenomenon (1) · ST Elevation Myocardial Infarction (1)
Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiomyopathies (1) · Cardiovascular Diseases (1) · Coronary Disease (1) · Heart Diseases (1) · Infarction (1) · Ischemia (1) · Myocardial Ischemia (1) · Necrosis (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Postoperative Complications (1) · Reperfusion Injury (1) · Vascular Diseases (1)
dapagliflozin (1) · empagliflozin (1)
Egypt (1)